Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Trastuzumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention. Browse Trastuzumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
678
Shown on this page
12
Current sort
Recently updated
Therapy scope
Trastuzumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Trastuzumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 157–168 of 678 matching trials for Trastuzumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

NCT03125928
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Recruiting Phase 2 Interventional

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

NCT04329065
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab, Pertuzumab, Docetaxel, Carboplatin, Ultrasound Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting Phase 2 Interventional Results available

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

NCT03587740
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
14
States / cities
Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting No phase listed Observational Results available

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

NCT03983382
View directory record Official record
Conditions
Breast Cancer
Interventions
Left Ventricular Ejection Fraction
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Recruiting Phase 2 Interventional

A Study of Surgery and Radiotherapy in People With Breast Cancer

NCT07053085
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
Procedure · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting No phase listed Observational

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

NCT06663787
View directory record Official record
Conditions
Breast Cancer, Metastatic, HER2 + Breast Cancer
Interventions
Trastuzumab (Herceptin), SIgnatera
Drug · Diagnostic Test
Lead sponsor
Nagoya City University
Other
Eligibility
20 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Carlos, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Recruiting Phase 2 Interventional

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

NCT05672524
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma, Rectal Cancer
Interventions
Trastuzumab, Tucatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

NCT05319873
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Carboplatin, Docetaxel, Fulvestrant, Pertuzumab, Quality-of-Life Assessment, Ribociclib, Trastuzumab, Tucatinib
Drug · Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

NCT04439110
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trastuzumab Emtansine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

NCT06828588
View directory record Official record
Conditions
Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions
[68Ga]Ga-ABY-025
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 18, 2026, 9:11 PM EDT
Recruiting Phase 2 Interventional

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

NCT07220135
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, Docetaxel, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 9:11 PM EDT

About this Trastuzumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Trastuzumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Trastuzumab.